Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Biotricity Inc. Market Cap
From what 0 stock analysts predict, the share price for Biotricity Inc. (BTCY) might decrease by 100% in the next year. This is based on a 12-month average estimation for BTCY. Price targets go from $ to $. The majority of stock analysts believe BTCY is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned BTCY 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Biotricity Inc. to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on BTCY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of BTCY.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Kevin Dede HC Wainwright & Co. | Neutral | Downgrade | Nov 20, 2023 | |
| Kevin Dede HC Wainwright & Co. | Buy | $4 | Reiterates | Jul 5, 2023 |
| Kevin Dede HC Wainwright & Co. | Buy | $2 | Reiterates | Feb 15, 2023 |
| Allen Klee Maxim Group | Hold | Downgrade | Jul 15, 2022 | |
| Kevin Dede HC Wainwright & Co. | Buy | $2 | Maintains | Jul 15, 2022 |
Lake Street | Buy | Initiates | Mar 7, 2022 | |
HC Wainwright & Co. | Buy | Initiates | Nov 23, 2021 | |
Northland Capital Markets | Outperform | Initiates | Jul 1, 2021 |
When did it IPO
N/A
Staff Count
55
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Dr. Waqaas Al-Siddiq Ph.D.
Market Cap
$10.2M
In 2023, BTCY generated $9.6M in revenue, which was a increase of 26.00% from the previous year. This can be seen as a signal that BTCY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 21 Aug 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Company shows continued progress towards cash-flow break even and profitability Recurring Technology Fee (SaaS) revenue - over 94% of total revenue with a 76% gross margin, which rose over 400 basis points and is expected to continue to trend higher Gross margins improved significantly to 73.8 from 63.5% in the same period last year, and 59.6% 2 years earlier Reduced SG&A to $3 million, down 16% compared to same period last year Operating loss of $1.1 million, indicated efficiency gains of $1.2 million from the preceding year quarter - a 51.8% improvement Growth in revenue of 6% YOY to $3.2 million EBITDA and Adjusted EBITDA improved by 18.9% and 49.8%, respectively, from the corresponding period in the prior year; Quarter over preceding Quarter, EBITDA improved by $1M, or 36%, whereas Adjusted EBITDA improved by $1.5M or 59%. Comprehensive loss was reported at $6.9 million, due to one-time non-cash items of $3.2 million; removing these would have resulted in a net loss of $3.7 million, consistent with prior year levels of $3.8 million due to interest rate increases that countered the impact of efficiency gains REDWOOD CITY, CA / ACCESSWIRE / August 21, 2024 / Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the first quarter of fiscal 2025 year ended June 30, 2024.
Fri, 26 Jul 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (Nasdaq:LOBO) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 27, at 7 p.m.
Mon, 22 Jul 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - REDWOOD CITY, CA / ACCESSWIRE / July 22, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced ongoing improvements in operational efficiency, scalability and margin performance driven by the latest enhancements to the company's proprietary AI Cloud platform. The latest version of Biotricity's AI Cloud has improved the company's tech stack efficiency by 20%, which is expected to result in a topline margin improvement of 200 to 300 basis points (2 to 3%) in the coming quarters.
Fri, 19 Jul 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m.
Wed, 10 Jul 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - REDWOOD CITY, CA / ACCESSWIRE / July 10, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced the launch of a new cardiac monitoring pilot program with a prominent hospital group encompassing 60 sites spread across multiple states. Biotricity's cardiac monitoring solution is the only three-channel connected solution in the world.
Thu, 11 Jul 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - REDWOOD CITY, CA / ACCESSWIRE / July 11, 2024 / Biotricity Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its accelerated timeline to achieving EBITDA positive. The company now expects to reach this significant milestone before the end of calendar 2024, earlier than previously anticipated.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
